The Japanese pharmaceutical company Kyowa Kirin Co. plans to sell shares in the Chinese division of the Hong Kong company WinHealth Pharma Group Co. for 15 billion yen ($100 million) as part of the ...

Kyowa Kirin ploughed ahead with KW-6356 despite the reservations of its former partner Lundbeck, which held the rights to KW-6356 outside Asia before handing them back to the Japanese company.

Outside the U.S., Kyowa Kirin will lead development, regulatory and commercial strategy and is responsible for commercializing ziftomenib. Kura will be eligible to receive tiered double-digit ...

Kura Oncology (NASDAQ:KURA) stock slid 17% post-market after the company announced a collaboration deal with Japan's Kyowa Kirin (OTCPK:KNBWY) for its leukemia drug candidate ziftomenib worth up ...

Under the deal, Kyowa Kirin will pay BridgeBio $100M upfront, plus royalties up to a high-20s percentage on sales of the product in Japan and potential milestone payments.